Dr. Nicholas DiBella
Claim this profileRocky Mountain Cancer Centers-Boulder
Expert in Breast Cancer
Expert in Lung Cancer
103 reported clinical trials
193 drugs studied
About Nicholas DiBella
Education:
- Earned a Medical degree (MD) from an unspecified institution.
Experience:
- Founded Rocky Mountain Cancer Centers (RMCC) in 1992 and served as its former president.
- Served as Chairman of the Board for the Colorado Cancer Research Program.
- Held the position of Chairman for the US Oncology Hematology Research Committee.
- Played a key role in establishing The US Oncology Network, connecting over 1,400 oncologists nationwide.
- Retired as Medical Director at Rocky Mountain Breast Specialists.
Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 positive
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Nicholas DiBella is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Financial Navigation
for Cancer Patients
This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, education and connections to appropriate resources to reduce financial barriers to healthcare and minimize financial stress and burden. CostCOM may improve adherence to care and decrease financial burden in patients with cancer.
Recruiting1 award N/A
More about Nicholas DiBella
Clinical Trial Related6 years of experience running clinical trials · Led 103 trials as a Principal Investigator · 49 Active Clinical TrialsTreatments Nicholas DiBella has experience with
- Nivolumab
- Pembrolizumab
- Cisplatin
- Atezolizumab
- Intensity-Modulated Radiation Therapy
- Fluorouracil
Breakdown of trials Nicholas DiBella has run
Breast Cancer
Lung Cancer
Breast cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nicholas DiBella specialize in?
Nicholas DiBella focuses on Breast Cancer and Lung Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Nicholas DiBella currently recruiting for clinical trials?
Yes, Nicholas DiBella is currently recruiting for 46 clinical trials in Boulder Colorado. If you're interested in participating, you should apply.
Are there any treatments that Nicholas DiBella has studied deeply?
Yes, Nicholas DiBella has studied treatments such as Nivolumab, Pembrolizumab, Cisplatin.
What is the best way to schedule an appointment with Nicholas DiBella?
Apply for one of the trials that Nicholas DiBella is conducting.
What is the office address of Nicholas DiBella?
The office of Nicholas DiBella is located at: Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado 80304 United States. This is the address for their practice at the Rocky Mountain Cancer Centers-Boulder.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.